Palonosetron in CINV and RINV: 2013 Evidence Update
2026-09-05
Fabi and Malaguti’s 2013 review examined how palonosetron hydrochloride differs from earlier 5-HT3 receptor antagonists through higher receptor affinity and a longer half-life. Its most meaningful clinical implication was stronger support for delayed chemotherapy-induced nausea and vomiting prevention after moderately emetogenic chemotherapy, while multiple-day chemotherapy and several radiotherapy settings remained areas for further study.
OCT2 and MATE1 Inhibition by Antiemetics
2026-09-04
George and colleagues examined how five 5-HT3 antagonist antiemetics inhibit the renal organic cation transporters OCT2 and MATE1. Their cell-based data identify transporter-specific potency differences and show that ondansetron can impair vectorial cation transport, supporting closer evaluation of renal drug–drug interactions.
Gamithromycin PK/PD in a Murine Lung Model
2026-09-04
Yang et al. integrated unbound pharmacokinetics with antibacterial outcomes in a neutropenic mouse lung infection model of Pasteurella multocida infection. Their analysis identified fAUC0–24/MIC as the exposure index most closely associated with bacteriostatic, bactericidal, and eradication-level effects, providing a quantitative basis for dose-regimen optimization.
AICAR Phosphate: From AMPK to Apoptosis
2026-09-03
A mechanistic and translational perspective on AICAR phosphate (Acadesine), linking AMPK signaling, mitochondrial apoptosis, B-CLL research, and hypoxia-associated barrier biology while defining practical validation strategies and study limitations.
L-Phenylephrine in α1A Signaling Workflows
2026-09-03
L-Phenylephrine provides a practical α1A-selective probe for studying vasoconstriction, baroreflex control, cardiomyocyte stress responses, and neural progenitor biology. This workflow-focused guide connects receptor pharmacology with telemetry, cell-based assays, sex-aware cardiovascular design, and troubleshooting strategies.
Gamithromycin PK/PD in Bovine Respiratory Disease
2026-09-02
This clinical pharmacology study linked gamithromycin exposure in pulmonary epithelial lining fluid (PELF) with treatment outcomes in naturally occurring bovine respiratory disease. Its combination of pathogen-specific MIC testing, nonlinear mixed-effects modeling, and effect-site pharmacokinetics showed why PELF AUC/MIC can provide more clinically relevant insight than plasma exposure alone.
Dual HER2–VEGFR2 Targeting in TNBC
2026-09-02
The reference study evaluates lapatinib plus Telatinib in HER2-negative MDA-MB-231 triple-negative breast cancer cells, linking dual tyrosine kinase inhibition with reduced proliferation, invadopodia formation, and angiogenic tube formation. Its main contribution is a pathway-level preclinical rationale for further testing, while the in vitro design does not establish target engagement, pharmacological synergy, or clinical efficacy.
AMPK–SQSTM1 Feedback Under Metabolic Stress
2026-09-01
The 2024 Autophagy study identifies a double-positive feedback loop in which AMPK and SQSTM1/p62 reinforce one another during metabolic stress, jointly activating AMPK and NFE2L2/NRF2 antioxidant defenses. Its mechanistic model connects lysosomal deacidification, TFEB/TFE3 regulation, ROS-dependent TAK1 activation, KEAP1 degradation, and lysosomal AMPK assembly, offering a framework for interpreting stress adaptation in cancer cells.
X-Gal Workflows for Cloning and Reporter Assays
2026-08-31
Turn β-galactosidase activity into a fast visual decision with optimized X-Gal workflows for blue-white colony screening, molecular cloning, and lacZ reporter experiments. Practical solvent, plating, control, and troubleshooting guidance helps distinguish genuine recombinant clones from assay artifacts.
Mitoxantrone HCl: DNA Topoisomerase II Inhibitor
2026-08-31
Mitoxantrone HCl is a DNA topoisomerase II inhibitor that disrupts DNA cleavage and ligation, producing DNA damage and cell-cycle interference. Research data also support ERα interdomain disruption, apoptosis induction in stem cells, and applications in leukemia, multiple sclerosis, and pancreatic cancer cell viability studies.
HyperFluor 488 Goat Anti-Rabbit IgG Guide
2026-08-30
HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody is a fluorescent secondary reagent for detecting rabbit IgG primary antibodies in immunofluorescence, flow cytometry, and fluorescence microscopy. It should not be assumed suitable for non-rabbit primaries, unvalidated live-cell workflows, or multiplex assays without appropriate controls.
Diethylmaleate and GST Resistance in M. usitatus
2026-08-29
Dong and colleagues show that glutathione S-transferase activity is not merely associated with lambda-cyhalothrin resistance in Megalurothrips usitatus but helps sustain antioxidant defenses during insecticide exposure. Pharmacological inhibition with diethyl maleate reduced antioxidant capacity and markedly increased insecticide sensitivity, providing a functional framework for studying redox-dependent resistance.
OMV mRNA Display for Personalized Tumor Vaccines
2026-08-29
This study developed genetically engineered bacterial outer membrane vesicles (OMVs) that rapidly bind antigen-encoding mRNA and promote delivery into dendritic cells. By combining L7Ae-mediated RNA capture with listeriolysin O-mediated endosomal escape, the platform generated antitumor responses, complete tumor regression in a subset of mice, and durable immune protection.
Disulfiram in Cancer Research: Protocols & Insights
2026-08-28
Disulfiram is more than a clinically used anti-alcoholism drug: it supports proteasome assays, copper-dependent cancer studies, and genotype-guided investigations of APC-deficient colorectal cancer. This practical guide translates its ALDH2-linked activity, proteasomal chymotrypsin-like activity inhibition, and apoptosis readouts into reproducible workflows.
L-Phenylephrine in Sex-Aware Adrenergic Assays
2026-08-28
L-Phenylephrine enables receptor-resolved investigation of α1A-adrenergic signaling alongside sex-dependent cardiovascular physiology. This article translates telemetry, baroreflex, and hormone-manipulation findings into practical assay decisions without conflating an α1A agonist challenge with chronic angiotensin II hypertension.
458 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page